<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133613</url>
  </required_header>
  <id_info>
    <org_study_id>09-OA-003</org_study_id>
    <nct_id>NCT01133613</nct_id>
  </id_info>
  <brief_title>Double-Blind, Randomized, Single Dose Escalation Safety Study of Intraarticular Bone Morphogenic Protein (38A BMP-7) in Subjects With Osteoarthritis (OA) of the Knee</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Biotech</source>
  <brief_summary>
    <textblock>
      The objective of the study is to determine the safety and tolerability of two different
      formulations of BMP-7 for the treatment of osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (physical examination, vital signs, clinical laboratory measurements, adverse events)</measure>
    <time_frame>Baseline, Day 2, Week 1, Week 2, Week 4, Week 8, Week 12, Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC pain and function</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and physician global VAS</measure>
    <time_frame>Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measurement (SF-36) and pain medication use</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.03 mg/ml BMP-7 or placebo via intraarticular knee injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 mg/ml BMP-7 or placebo via intraarticular knee injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 mg/ml BMP-7 or placebo via intraarticular knee injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bone morphogenetic protein 7</intervention_name>
    <description>Single intraarticular injection of BMP-7 or placebo on Day 1</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Ambulatory with a diagnosis of OA of the knee with symptoms for at least 6 months and
             pain on the majority of days in the last 30 days.

          -  &gt;40 years

          -  Radiographic evidence of at least one osteophyte in either knee at screening

        Exclusion Criteria

          -  Concurrent medical or arthritis condition that could interfere with evaluation of
             index knee joint (including fibromyalgia)

          -  Unwilling to abstain from NSAIDs and/or other analgesic medications for 48 hrs prior
             to assessments. Subjects can remain on acetaminophen up to 3.0 g daily.

          -  Received arthroscopic or open surgery to the index knee within 6 months of screening

          -  History of joint replacement surgery (index knee).

          -  Corticosteroid, short acting hyaluronic acid, or other intraarticular injections of
             the index knee within 3 months of screening

          -  Long acting hyaluronic acid injection of the index knee within 6 months of screening

          -  History of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing
             spondylitis, lymphoma, and arthritis associated with inflammatory bowel disease,
             sarcoidosis, amyloidosis or fibromyalgia.

          -  History of malignancy with the exception of resected basal cell, squamous cell of the
             skin, resected cervical atypia or carcinoma in situ.

          -  Female subject with reproductive capability.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Florida Medical Research Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2010</study_first_submitted>
  <study_first_submitted_qc>May 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2010</study_first_posted>
  <last_update_submitted>January 30, 2012</last_update_submitted>
  <last_update_submitted_qc>January 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

